BREAST CANCER

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.

At a live virtual event, Priyanka Sharma, MD, discussed the treatment options for patients with metastatic breast cancer who develop triple-negative breast cancer.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the next steps following the successful outcomes of the phase 3 DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Results from the GeparOLA study show that neoadjuvant olaparib did not achieved better efficacy compared with carboplatin and paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Longer follow-up in the phase 3 STIC CTC trial substantiates that the CTC-based choice is safe in patients with metastatic breast cancer, according to investigators.

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.

Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.

Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.

Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.

According to Ruth O'Regan, MD, BCI is the first genomic assay to demonstrate benefit from ovarian suppression.

Poorer outcomes were shown in Black patients with hormone receptor-positive breast cancer, including in patients with similar 21-gene recurrence scores.

Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.

The data from 2 years post primary efficacy analysis of monarchE study showed that adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival.

Residual disease after neoadjuvant chemotherapy tumor microenvironment of metastasis doorway density is higher in Black women, potentially explaining poorer outcomes.

Pre- and postmenopausal patient with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, according to RxPONDER PRO substudy results presented during SABCS 2022.

Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer

Erica Stringer-Reasor, MD, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.

Lajos Pusztai, MD, DPhil, discusses recent data from the phase 3 KEYNOTE-522 trial of patients with triple-negative breast cancer.

Fast track designation has been granted to REM-001 therapy for patients with cutaneous metastatic breast cancer based on positive data from 4 phase 2/3 studies.

Lisa A. Carey, MD, ScM, discusses the recent trends in treatment for triple-negative breast cancer.

Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.

With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.

Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.

Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.